Moderna insists its Covid vaccine DOES work on new coronavirus variants but the firm is already developing a 'booster' after current jab was less effective against South African strain
- Kent strain had 'no significant impact' on jab, which UK has bought 17m doses of
- Moderna said vaccine up to six times less potent against South African variant
- US firm said it's now developing a booster jab to combat the South African strainModerna's coronavirus vaccine is just as effective at protecting against the Kent variant as it was older versions of the disease, the company claimed today.
In a huge boost to Britain's vaccination programme, the US firm said laboratory tests found the new variant had 'no significant impact' on the jab.
Britain has ordered 17 million doses of the Moderna jab, which was 95 per cent effective at blocking the original Covid strain. They are due to arrive in spring. The researchers took blood samples from patients who had received the vaccine and exposed them to the various mutated strains of the virus.
They found it still offered protective levels of immunity against Covid-19, but admitted that the jab may be up to six times less potent against the South African variant which is causing international concern.
Moderna claimed that although there was a six-fold reduction in neutralising antibodies, the levels remained high enough to be able to stop the virus if it got into the body.
Antibodies are substances made by the immune system that are key to destroying viruses or marking them for destruction by white blood cells.
Antibodies are a major part of the immunity that is created by vaccines – although not the only part – so if the virus continues evolving to escape from them it could mean that vaccines have to be redesigned and given out again.
Moderna is now developing a booster jab, to be taken after the original two-dose vaccine, to provide extra protection against the South African variant.
The South African strain — called B.1.351 — has key mutations on its spike protein which make scientists fear might make it hard for the immune system to recogniseStéphane Bancel, chief executive officer of Moderna, said: 'As we seek to defeat the Covid-19 virus, which has created a worldwide pandemic, we believe it is imperative to be proactive as the virus evolves.
'We are encouraged by these new data, which reinforce our confidence that the Moderna Covid-19 vaccine should be protective against these newly-detected variants.
'Out of an abundance of caution and leveraging the flexibility of our mRNA platform, we are advancing an emerging variant booster candidate against the variant first identified in the Republic of South Africa into the clinic to determine if it will be more effective to boost titers [antibodies] against this and potentially future variants.'
It means all three of the UK's main jabs - including Oxford University/Astrazeneca's and Pfizer/BioNTech's - are shown to be just as effective on the mutant strain.
The Kent variant was first picked up in the South East in late September and quickly went on to become the dominant strain in the UK, sparking a winter wave of infections and hospital admissions that plunged England into its third national lockdown.
UK studies have shown the variant is between 50 and 70 per cent more infectious than the original strain.
A mutation on the variant's spike protein called N501Y — which protrudes from the coronavirus and hijacks human cells — is thought to make it better at infecting people.
But the good news is that it doesn't appear to have changed the virus so much that immune cells triggered by vaccines based on a version of the virus from last year don't recognise it.
The other major vaccine developers said they were keeping a close eye on the virus's mutation and laying the groundwork for new jabs in case they are needed in future.
For Pfizer and Moderna, which produce theirs using genetic code called mRNA, it could be as basic as changing the genetic code on a computer and regenerating all of the RNA samples.
For Oxford and Janssen, however, which attach part of the real coronavirus to a living cold virus from a chimp, the companies must go through the process of growing all of these natural components, which slows down development. It takes Oxford around three months to make a batch.
AstraZeneca's executive vice-president, Sir Mene Pangalos, pointed to this as a reason behind delays to Britain's vaccine supply in a meeting with MPs last week.
He said: 'You have to grow cells, and cells divide at a certain speed – you can’t do any faster than the speed at which the cells divide.'
AstraZeneca, which produces a vaccine designed by the University of Oxford, said it is already starting work on designing new vaccines behind the scenes.
A spokesperson for the company said: 'The University of Oxford and labs across the world are carefully assessing the impact of new variants on vaccine effectiveness, and starting the processes needed for rapid development of adjusted Covid-19 vaccines if these should be necessary.'
Pfizer is also understood to be working on understanding the new variants and how it could adapt its vaccine to tackle them.
But the fact the South African variant may be able to slip by the vaccines will be a huge cause for concern.
There have already been 77 cases of that strain in the UK, although this number is likely to be far higher because Public Health England only analyses one in 10 random positive samples.
What variants are causing panic around the world?
No comments: